Sage Mountain Advisors LLC Trims Stock Holdings in Danaher Co. (NYSE:DHR)

Sage Mountain Advisors LLC cut its holdings in shares of Danaher Co. (NYSE:DHR) by 12.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,077 shares of the conglomerate’s stock after selling 294 shares during the quarter. Sage Mountain Advisors LLC’s holdings in Danaher were worth $480,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Nicholas Hoffman & Company LLC. raised its stake in Danaher by 2.3% during the 4th quarter. Nicholas Hoffman & Company LLC. now owns 1,899 shares of the conglomerate’s stock valued at $439,000 after acquiring an additional 43 shares in the last quarter. Drive Wealth Management LLC raised its stake in Danaher by 3.1% during the 4th quarter. Drive Wealth Management LLC now owns 1,485 shares of the conglomerate’s stock valued at $344,000 after acquiring an additional 44 shares in the last quarter. Trust Investment Advisors raised its stake in Danaher by 1.8% during the 4th quarter. Trust Investment Advisors now owns 2,811 shares of the conglomerate’s stock valued at $650,000 after acquiring an additional 49 shares in the last quarter. New Hampshire Trust raised its stake in Danaher by 0.3% during the 3rd quarter. New Hampshire Trust now owns 14,438 shares of the conglomerate’s stock valued at $3,582,000 after acquiring an additional 50 shares in the last quarter. Finally, Connolly Sarah T. increased its position in shares of Danaher by 0.5% during the 3rd quarter. Connolly Sarah T. now owns 9,599 shares of the conglomerate’s stock valued at $2,382,000 after purchasing an additional 50 shares during the period. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Citigroup lifted their price target on Danaher from $255.00 to $280.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Raymond James lifted their price target on Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. KeyCorp lifted their price target on Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. Finally, Royal Bank of Canada lifted their target price on Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Six research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $268.27.

Insider Activity

In other news, Director Teri List sold 3,289 shares of Danaher stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total transaction of $816,724.48. Following the transaction, the director now owns 19,726 shares in the company, valued at $4,898,360.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, SVP Daniel Raskas sold 23,757 shares of Danaher stock in a transaction on Monday, February 26th. The stock was sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the sale, the senior vice president now owns 38,102 shares of the company’s stock, valued at $9,601,704. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Teri List sold 3,289 shares of Danaher stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total value of $816,724.48. Following the sale, the director now directly owns 19,726 shares of the company’s stock, valued at approximately $4,898,360.32. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 32,957 shares of company stock worth $8,265,802. 10.90% of the stock is owned by corporate insiders.

Danaher Stock Performance

Shares of DHR stock opened at $236.08 on Tuesday. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $259.00. The company has a current ratio of 1.68, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $174.83 billion, a price-to-earnings ratio of 36.95, a P/E/G ratio of 3.95 and a beta of 0.83. The stock’s fifty day simple moving average is $248.72 and its 200-day simple moving average is $230.39.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.18. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The business had revenue of $6.41 billion for the quarter, compared to the consensus estimate of $6.10 billion. During the same quarter in the previous year, the company posted $2.87 earnings per share. Danaher’s revenue for the quarter was down 10.2% compared to the same quarter last year. On average, sell-side analysts predict that Danaher Co. will post 7.62 earnings per share for the current fiscal year.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be issued a dividend of $0.27 per share. This is an increase from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.46%. Danaher’s payout ratio is currently 16.90%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.